Stockscreener 앱 받기
7.05
2.22%
-0.16
시간 외 거래:
7.05
전일 마감가:
$7.21
열려 있는:
$7.26
하루 거래량:
630.28K
Relative Volume:
0.70
시가총액:
$323.57M
수익:
$10.32M
순이익/손실:
$-89.93M
주가수익비율:
-2.9297
EPS:
-2.4064
순현금흐름:
$-88.63M
1주 성능:
-12.53%
1개월 성능:
-30.27%
6개월 성능:
-57.04%
1년 성능:
+35.06%
1일 변동 폭
$7.03
$7.295
1주일 범위
$7.03
$8.53
52주 변동 폭
$5.04
$25.95
Bioage Labs Inc Stock (BIOA) Company Profile
명칭
Bioage Labs Inc
전화
510-806-1445
주소
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, TEVA, HLN, ZTS, VTRS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
7.05 | 323.57M | 10.32M | -89.93M | -88.63M | -2.4064 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-27 | 개시 | Roth Capital | Buy |
| 2026-05-13 | 개시 | BTIG Research | Buy |
| 2026-03-27 | 개시 | Needham | Buy |
| 2026-02-25 | 개시 | Oppenheimer | Outperform |
| 2026-02-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2026-01-27 | 개시 | Piper Sandler | Overweight |
| 2025-12-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2024-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-21 | 개시 | Citigroup | Buy |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-21 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BioAge Labs to Present at Upcoming Investor Conferences - markets.businessinsider.com
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection? - Stocktwits
BIOAGE Labs Inc (BIOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioAge Labs at Morgan Stanley conference: BGE-102 gains focus - Investing.com
Analysts Offer Insights on NA Companies: Fair Isaac (FICO), Freeport-McMoRan (FCX) and BioAge Labs, Inc. (BIOA) - theglobeandmail.com
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $35 - Moomoo
BioAge Labs at Cantor conference: shifts focus to retina By Investing.com - Investing.com Canada
Transcript : BioAge Labs, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11 - marketscreener.com
BIOA: Phase II trials for BGE-102 target DME and metabolic diseases, with pivotal data expected next year - TradingView
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema - The Manila Times
A daily pill for diabetic eye disease enters a Phase 2 trial - Stock Titan
BioAge Labs remains a buy despite 40% drop, bac... - Pluang
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off (BIOA) - Seeking Alpha
Bioage Labs Market Sentiment - Benzinga España
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know - qz.com
BIOA Q2 2026 Earnings: Narrower-Than-Expected Loss Underscores Clinical-Stage DisciplineEarnings Volatility Report - dars.gov.et
354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC - MarketBeat
BioAge Labs, Inc.: Shareholders Board Members Managers and Company Profile | US09077V1008 - marketscreener.com
Cormorant Asset Management (BIOA) discloses 5.38% BioAge Labs ownership stake - Stock Titan
214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP - MarketBeat
BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
We're Not Very Worried About BioAge Labs' (NASDAQ:BIOA) Cash Burn Rate - Moomoo
BioAge Labs (BIOA) Retreats 2.3% Toward Key Support as Momentum FadesVolatility Term Structure - careplusvn.com
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Hold Rating, Cuts Target Price to $20 - Moomoo
Roth MKM Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV) - The Globe and Mail
BIOA News & Events - Intellectia AI
BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIOAGE Labs Inc (BIOA) Stock News Today - TradingKey
A Quick Look at Today's Ratings for BioAge Labs(BIOA.US), With a Forecast Between $21 to $73 - Moomoo
BioAge Labs, Inc. Stock 12‑Month Price Target Cut to $35.62, Implies 224% Upside - TradingView
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BioAge Labs (NASDAQ:BIOA) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
BioAge Labs, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
BIOA: BGE-102 clinical trials advanced, net loss increased, and cash reserves remain strong - TradingView
BioAge Labs reports Q2 2026 net loss $26.1M, cash and securities $381.3M; BGE-102 Phase 2 dosing underway - TradingView
BioAge Labs, Inc. Q2 2026: Revenue $2.45M, EPS $(0.58) — 10-Q Summary - TradingView
BioAge Labs (NASDAQ: BIOA) builds $381.3M cash buffer as BGE-102 advances - Stock Titan
BioAge Labs | 10-Q: Q2 2026 Earnings Report - Moomoo
BioAge Labs Reports Q2 2026 Results, Doses First Patient in QUELL-CV and Advances BGE-102 Clinical Development - Quiver Quantitative
BioAge Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BioAge's BGE-102 Enters Obesity Trial; Eye Study Planned - Stock Titan
Price to earnings forward of BioAge Labs, Inc. – SWB:Y7G - TradingView
BIOA Q2'26 Earnings: revenue estimate is 1.50M USD - TradingView
Piper Sandler Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $73 - Moomoo
BioAge Labs posts partial recovery after deep selloff, rises 19% (BIOA:NASDAQ) - Seeking Alpha
Weekly Recap: ZEUS miss lifts BGE-102 and Analysts cut BIOA PTs, keep Buy - TradingView
Janus Henderson Group PLC Acquires 1,685,063 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
BTIG Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Bioage Labs Inc (BIOA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.69%
자본화:
|
볼륨(24시간):